Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium.
Advanced urothelial carcinoma is an aggressive form of cancer associated with a high mortality rate. Cisplatin-based chemotherapy regimens have improved survival of patients with this disease. A significant number of patients with urothelial carcinoma have impaired renal or cardiac function, poor performance status, or other comorbidities that preclude the use of cisplatin-based therapy. This review discusses alternative treatment regimens that have been evaluated to identify effective and less toxic therapeutic strategies for cisplatin-ineligible patients, as well as ongoing clinical trials that focus on this patient population.
Vaughn
David J
DJ
Abramson Cancer Center of the University of Pennsylvania, 16 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104, USA. david.vaughn@uphs.upenn.edu <david.vaughn@uphs.upenn.edu>
D000971:Antineoplastic Combined Chemotherapy Protocols; D016190:Carboplatin / Q000627:therapeutic use; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy; D002945:Cisplatin / Q000009:adverse effects*; D015897:Comorbidity; D006801:Humans; D017671:Platinum Compounds / Q000009:adverse effects*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D017671:Platinum Compounds; D016190:Carboplatin; D002945:Cisplatin